Salarius Pharmaceuticals, Inc. SLRX
At closeJan 7, 2026, 4:00 PM EST
After hours · Jan 7, 4:00 PM ET
52-week range unavailable
- YTD
- +29.47%
- 1 year
- -96.73%
- Market cap
- 4.92M
- Shares out
- 1.44M
- Forward P/E
- -0.17
- YTD return
- +29.47%
- 1-year return
- -96.73%
- Volume
- 5.96M
- Open
- 0.706
- Previous close
- 0.84
- Day's range
- 0.6865 – 0.8976
- Beta
- 0.93
2Y -78.2302 (-98.96%)
Key statistics
- Enterprise value
- -1.26M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.13M
- Total cash
- 3.27M
- Total debt
- 0
- Return on equity
- -119.83%
- Short % of float
- 4.55%
- 50-day average
- 1.52
- 200-day average
- 2.59
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.76 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | -53.60 | -2.37 | +51.23 | +95.58% |
| May 13, 2024 | Mar 1, 2024 | -53.60 | -3.28 | +50.32 | +93.88% |
| Mar 22, 2024 | Dec 1, 2023 | -8.08 | -1.76 | +6.32 | +78.22% |
| Nov 9, 2023 | Sep 1, 2023 | -8.56 | -5.20 | +3.36 | +39.25% |
| Aug 10, 2023 | Jun 1, 2023 | -10.08 | -11.44 | -1.36 | -13.49% |
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- salariuspharma.com
News
12 Health Care Stocks Moving In Monday's Intraday Session - 12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Thursday's Intraday Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on SLRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARTHUR DAVID J | Chief Executive Officer | Stock Award(Grant) | Feb 12, 2023 | 49,135 |
| BURLESON TESS | Director | Stock Award(Grant) | Jan 2, 2023 | 2,722 |
| HANISH ARNOLD C | Director | Stock Award(Grant) | Jan 2, 2023 | 3,294 |
| LAMMERS PAUL I | Director | Stock Award(Grant) | Jan 2, 2023 | 1,718 |
| LIEBER JONATHAN I | Director | Stock Award(Grant) | Jan 2, 2023 | 2,940 |
| MCCREEDY BRUCE J JR | Director | Stock Award(Grant) | Jan 2, 2023 | 1,788 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.22% | 3,189 | 5.01K | Sep 29, 2024 |
| Citigroup Inc. | 0.11% | 1,610 | 2.53K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 260 | 408 | Sep 29, 2024 |
| Osaic Holdings Inc | 0.01% | 162 | 254 | Sep 29, 2024 |
| Blackrock Inc. | 0.00% | 1 | 1 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 18 | 28 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.40% | 5,738 | 9.01K | Oct 30, 2024 |
| Listed Funds Tr-Horizon Kinetics Medical ETF | 0.26% | 3,723 | 5.84K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.15% | 2,138 | 3.36K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.13% | 1,820 | 2.86K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 321 | 503 | Oct 30, 2024 |